AusperBio is a clinical-stage biopharmaceutical company advancing oligonucleotide and targeted delivery technologies, with an initial focus on a functional cure for chronic hepatitis B. Its proprietary Med-Oligo™ ASO platform, combined with targeted delivery conjugation, enhances ASO therapeutics and enables treatment across a broad range of diseases.